Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
NCT03328130
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class
Stopped
lack of financing
Conditions
Retinitis Pigmentosa
Interventions
BIOLOGICAL:
AAV2/5-hPDE6B
Sponsor
eyeDNA Therapeutics